AngioDynamics, Inc. (NASDAQ:ANGO) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP cut its stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 31.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 260,700 shares of the medical instruments supplier's stock after selling 121,500 shares during the period. Two Sigma Advisers LP owned about 0.64% of AngioDynamics worth $2,388,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in AngioDynamics during the 4th quarter valued at about $28,000. R Squared Ltd purchased a new position in AngioDynamics during the 4th quarter valued at about $49,000. US Bancorp DE increased its position in AngioDynamics by 1,938.0% during the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock valued at $61,000 after purchasing an additional 6,376 shares during the period. Quinn Opportunity Partners LLC purchased a new position in AngioDynamics during the 4th quarter valued at about $92,000. Finally, ProShare Advisors LLC purchased a new position in AngioDynamics during the 4th quarter valued at about $100,000. 89.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $16.00 target price (up previously from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

AngioDynamics Price Performance

NASDAQ ANGO traded down $0.50 during trading on Monday, reaching $9.70. 1,137,231 shares of the company's stock traded hands, compared to its average volume of 563,615. The firm has a market cap of $393.89 million, a price-to-earnings ratio of -1.72 and a beta of 0.58. The company's 50 day simple moving average is $9.47 and its two-hundred day simple moving average is $9.61. AngioDynamics, Inc. has a 12-month low of $5.47 and a 12-month high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.00 million for the quarter, compared to analysts' expectations of $70.30 million. The firm's quarterly revenue was down 4.3% compared to the same quarter last year. Research analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.